BR112022001185A2 - Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos - Google Patents

Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos

Info

Publication number
BR112022001185A2
BR112022001185A2 BR112022001185A BR112022001185A BR112022001185A2 BR 112022001185 A2 BR112022001185 A2 BR 112022001185A2 BR 112022001185 A BR112022001185 A BR 112022001185A BR 112022001185 A BR112022001185 A BR 112022001185A BR 112022001185 A2 BR112022001185 A2 BR 112022001185A2
Authority
BR
Brazil
Prior art keywords
polymerosomes
population
eliciting
populations
immune response
Prior art date
Application number
BR112022001185A
Other languages
English (en)
Portuguese (pt)
Inventor
Kumar Khan Amit
Fabien Decaillot
Madhavan Nallani
Andrew Cornell Thomas
Original Assignee
Acm Biolabs Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acm Biolabs Pte Ltd filed Critical Acm Biolabs Pte Ltd
Publication of BR112022001185A2 publication Critical patent/BR112022001185A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BR112022001185A 2019-08-01 2020-08-03 Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos BR112022001185A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19189549 2019-08-01
EP20171327 2020-04-24
PCT/EP2020/071809 WO2021019102A2 (en) 2019-08-01 2020-08-03 A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes

Publications (1)

Publication Number Publication Date
BR112022001185A2 true BR112022001185A2 (pt) 2022-03-15

Family

ID=72148072

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001185A BR112022001185A2 (pt) 2019-08-01 2020-08-03 Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos

Country Status (9)

Country Link
US (1) US20220273792A1 (https=)
EP (1) EP4007597A2 (https=)
JP (1) JP7676030B2 (https=)
CN (1) CN114502191B (https=)
AU (1) AU2020322107A1 (https=)
BR (1) BR112022001185A2 (https=)
CA (1) CA3143533A1 (https=)
PH (1) PH12022550112A1 (https=)
WO (1) WO2021019102A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104936579B (zh) * 2012-11-19 2020-02-07 新加坡科技研究局 用于引发对免疫原的免疫响应的方法
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
US12384811B2 (en) 2019-04-05 2025-08-12 Academia Sinica Sialidase-resistant saccharide and method of making and using the same
KR102657261B1 (ko) * 2020-04-03 2024-04-15 조선대학교산학협력단 Ｃｏｖｉｄ－１９ 진단을 위한 재조합 코로나－１９ 바이러스 스파이크 단백질의 생산 및 이의 용도
WO2021214339A2 (en) * 2020-04-24 2021-10-28 Acm Biolabs Pte Ltd Vaccine against human-pathogenic coronaviruses
TWI870591B (zh) 2020-05-08 2025-01-21 中央研究院 嵌合流感疫苗
JP2023550094A (ja) * 2020-11-12 2023-11-30 ティースキャン セラピューティクス インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２免疫優性ペプチドの構築物及びその使用
JP2024500360A (ja) * 2020-12-11 2024-01-09 エイシーエム バイオラブズ プライベート リミテッド 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法
CN117597109A (zh) * 2021-02-02 2024-02-23 Acm 生物实验室私人有限公司 聚合物囊泡相关联的佐剂用于刺激免疫应答的单独使用
WO2022171182A1 (zh) * 2021-02-10 2022-08-18 斯微(上海)生物科技股份有限公司 一种治疗或者预防冠状病毒病突变株的疫苗试剂
WO2022180635A1 (en) * 2021-02-25 2022-09-01 Migvax Ltd. Oral compositions and use of same in vaccination
US20240181041A1 (en) * 2021-03-16 2024-06-06 The Wistar Institute Adenovirus SARS-CoV-2 Vaccine
US20220323569A1 (en) * 2021-03-30 2022-10-13 Qiang Chen Plant-produced vlps and ric vaccines
WO2022212505A1 (en) * 2021-03-30 2022-10-06 Arizona Board Of Regents On Behalf Of Arizona State University Optimal production of sars-cov-2 virus-like particles (vlps) produced in mammalian cells
BR112023005961A2 (pt) * 2021-04-12 2023-10-24 Academia Sinica Molécula de ácido nucleico modificada, vacina combinada, nanopartícula, nanocluster de mrna, método para prevenir ou tratar uma infecção por coronavírus, método para reforço de uma resposta imune adaptativa, peptídeo imunogênico e composição imunogênica
BR112023000666A2 (pt) * 2021-04-12 2023-10-24 Academia Sinica Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica
CN115337404A (zh) * 2021-05-12 2022-11-15 中国医学科学院基础医学研究所 细胞微颗粒在治疗呼吸道病毒性肺炎上的应用
WO2022251101A2 (en) * 2021-05-24 2022-12-01 nference, inc. Compositions and methods related to surge-associated sars-cov-2 mutants
WO2023004415A2 (en) * 2021-07-22 2023-01-26 University Of Miami Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments
CN113633764B (zh) * 2021-09-02 2024-05-14 中国食品药品检定研究院 一种含佐剂的新冠dna疫苗
IT202100023816A1 (it) * 2021-09-16 2023-03-16 Takis S R L Anticorpo contro SARS-CoV-2 e suoi usi in campo medico.
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
WO2023060220A1 (en) * 2021-10-07 2023-04-13 BioVaxys Inc. Methods of immunization against coronavirus
CN114470186B (zh) * 2022-02-17 2023-10-20 唐颐控股(深圳)有限公司 一种可吸入式纳米新冠疫苗的制备方法
AU2024252371B2 (en) 2023-04-08 2026-02-12 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
US12318485B2 (en) 2023-04-08 2025-06-03 Rock Biomedical, Inc. Methods and compositions for targeted delivery by polymersomes
WO2024238734A2 (en) 2023-05-17 2024-11-21 Rock Biomedical Inc. Mgat1 deficient cells and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
JP2002514397A (ja) * 1998-05-14 2002-05-21 コーリー ファーマシューティカル ゲーエムベーハー ＣｐＧオリゴヌクレオチドを用いる造血調節の方法
US6835394B1 (en) * 1999-12-14 2004-12-28 The Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
US20080181939A1 (en) * 1999-12-14 2008-07-31 Trustees Of The University Of Pennsylvania Polymersomes and related encapsulating membranes
EP2281033B1 (en) 2008-04-17 2014-10-15 Vin de Bona Trading Co Pte Post release modification of viral envelopes
US8323696B2 (en) 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
CN102460150B (zh) 2009-04-20 2015-05-20 新加坡科技研究局 囊泡系统及其用途
CN102917690B (zh) * 2010-03-19 2016-08-24 麻省理工学院 脂质囊泡组合物和使用方法
EP2601262A4 (en) 2010-08-05 2014-01-22 Agency Science Tech & Res VESIGN STRUCTURE WITH SEVERAL CHAMBERS AND METHOD FOR THEIR EDUCATION
EP4218808A3 (en) 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvant and vaccine compositions
DK2906717T3 (en) 2012-10-11 2019-04-01 Vin De Bona Trading Company Pte Ltd PROCEDURE FOR PAINTING MICROVESICS
CN104936579B (zh) 2012-11-19 2020-02-07 新加坡科技研究局 用于引发对免疫原的免疫响应的方法
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
WO2016055611A1 (en) * 2014-10-09 2016-04-14 Universität Basel Self-assembled nanostructures and methods of use thereof
US9636397B2 (en) 2015-03-24 2017-05-02 VaxLiant, LLC Adjuvant compositions and related methods
WO2019145475A2 (en) * 2018-01-25 2019-08-01 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
CN108969771B (zh) * 2018-08-07 2021-06-29 中国医学科学院生物医学工程研究所 甘露糖修饰的共载抗原和双免疫激动剂磷脂杂化聚合物囊泡及其制备方法与应用

Also Published As

Publication number Publication date
WO2021019102A3 (en) 2021-03-11
CN114502191A (zh) 2022-05-13
WO2021019102A2 (en) 2021-02-04
CA3143533A1 (en) 2021-02-04
JP2022543038A (ja) 2022-10-07
US20220273792A1 (en) 2022-09-01
AU2020322107A1 (en) 2022-02-03
EP4007597A2 (en) 2022-06-08
JP7676030B2 (ja) 2025-05-14
PH12022550112A1 (en) 2022-12-19
CN114502191B (zh) 2026-04-03

Similar Documents

Publication Publication Date Title
BR112022001185A2 (pt) Método de eliciamento de uma resposta imune administrando uma população de polimerossomos tendo um antígeno associado com uma população de polimerossomos tendo um adjuvante associado, bem como composições compreendendo as duas populações de polimerossomos
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
CO2017011245A2 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos
BR112017008042A2 (pt) métodos e composições para dosagem em terapia de célula adotiva
MX2021015775A (es) Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos.
MX379051B (es) Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos.
BR112016028816A2 (pt) combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório, e, kit.
BR112021019859A2 (pt) Vacinas de circovírus suíno tipo 3 (pcv3) e produção e seus usos
BRPI0912411A8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) ou de um fragmento da mesma, composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune, uso de muteína de interleucina humana-2 (muteína de hil-2) ou de uma seção da mesma, agete para formação de células t regulatórias (treg) em um organismo, método para tratamento e/ou profilaxia de uma doença autoimune em um organismo, método para formação de células t regulatórias (treg) em um organismo, método para formação de células t regulatórias (treg) in vitro.
BR112019014397A2 (pt) Composições de neisseria meningitidis e métodos das mesmas
BR112017020780A2 (pt) métodos de administração de inibidores de glutaminase
BR112017002440A2 (pt) vírus da diarreia epizoótica porcina mutante para utilização em uma vacina
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
BR112018015893A2 (pt) vacinas de câncer e métodos de tratamento usando as mesmas
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
MX2020003756A (es) Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile.
BR112015022582A2 (pt) molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo
BR112022020298A2 (pt) Vacinas, adjuvantes e métodos para gerar uma resposta imune
BR112012026007A2 (pt) método e composições para a inibição de células treg, bem como uso de células th1 alogênicas e uma fonte de antígenos
BR112023011605A2 (pt) Uso do peptídeo, método de tratamento de câncer ou infecções virais, e, combinação farmacêutica
BR112022014821A2 (pt) Tratamento envolvendo vacinação de antígeno e ligação de agentes que se liga a pd-l1 e cd137
BR112017002206A2 (pt) peptídeo derivado de koc1 e vacina incluindo o mesmo
MX2024001696A (es) Vacunas contra el virus de la enfermedad hemorragica del conejo (rhdv).
BR112021025286A2 (pt) Vacina contra o hiv com base em células t alogênicas para induzir a imunidade celular e humoral
BR112022027124A2 (pt) Formulações para promover a hidratação e métodos de uso das mesmas